Teva Pharmaceutical Industries (TEVA) Long-Term Debt Repayments: 2017-2025
Historic Long-Term Debt Repayments for Teva Pharmaceutical Industries (TEVA) over the last 4 years, with Sep 2025 value amounting to $444.0 million.
- Teva Pharmaceutical Industries' Long-Term Debt Repayments was N/A to $444.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 billion, marking a year-over-year change of. This contributed to the annual value of $1.6 billion for FY2024, which is 60.48% down from last year.
- As of Q3 2025, Teva Pharmaceutical Industries' Long-Term Debt Repayments stood at $444.0 million, which was down 80.70% from $2.3 billion recorded in Q2 2025.
- Teva Pharmaceutical Industries' Long-Term Debt Repayments' 5-year high stood at $5.2 billion during Q4 2021, with a 5-year trough of $296.0 million in Q2 2022.
- Its 3-year average for Long-Term Debt Repayments is $1.4 billion, with a median of $1.0 billion in 2023.
- In the last 5 years, Teva Pharmaceutical Industries' Long-Term Debt Repayments plummeted by 86.32% in 2022 and then skyrocketed by 173.97% in 2023.
- Teva Pharmaceutical Industries' Long-Term Debt Repayments (Quarterly) stood at $5.2 billion in 2021, then plummeted by 86.32% to $708.0 million in 2022, then surged by 173.97% to $1.0 billion in 2023, then reached $685.0 million in 2024, then spiked by 140.59% to $444.0 million in 2025.
- Its Long-Term Debt Repayments stands at $444.0 million for Q3 2025, versus $2.3 billion for Q2 2025 and $1.4 billion for Q1 2025.